Nevertheless, contrary to this original notion of mutual exclusivity of EGFR and KRAS mutations, NSCLC patients have been recently reported to harbor EGFR mutations along with those in KRAS [26,27]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.